BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Friday, September 18, 2026
📌TL;DR
The FDA approved Ultragenyx's Fayuvi (UX111) for Sanfilippo syndrome type A on Thursday, two days before its September 19 action date, with a rare pediatric Priority Review Voucher; the price was not disclosed and shipping begins within 30 to 60 days.
Bayer's Kerendia won FDA approval for chronic kidney disease associated with type 1 diabetes, the first new treatment for that population in more than 30 years per Bayer; FINE-ONE cut UACR 28% versus placebo at six months.
Amylyx's 30 day greenshoe window reached its expiry with no disclosure found; AMLX closed at 33.94, a fourteenth consecutive close below the $35.50 offer price.
Novo signed an up to $1.4B multi target oral macrocycle pact with Copenhagen's Orbis Medicines, and Roche paid Dualitas $36.5M upfront in a bispecific screening deal worth up to about $1B, per Fierce.
Roche's Lunsumio plus lenalidomide met the progression free survival primary in its Phase 3 confirmatory trial in follicular lymphoma; no figures were disclosed.
Electra Therapeutics raised $350M in its IPO per Endpoints, the 21st biotech IPO of 2026; ETRA had not traded by Thursday's close.
⚡ Executive Takeaway
We named this Forced Disclosure Week on Monday, and the verdict came in cleaner than we expected: deadlines only produce documents when a regulator holds the pen. The FDA published twice, both times early. The three corporate disclosures the calendar was supposed to force never arrived. Amylyx let its option window die in silence, because fourteen closes below the offer price had already answered the only question a closing release would have settled. Amgen finished the week without naming a single date. Roche won a pivotal trial Thursday and declined to attach a number to it.
The transferable lesson is that behavior discloses faster than filings. An option that goes unexercised against a hard deadline, a positive readout announced without its number, a stock that recovers with no news attached: each is a disclosure in everything but form, and the market graded all of them by Thursday's close. Next week the pen returns to the one party that publishes on schedule. Grail's briefing documents are due around Sunday, the first multi cancer early detection panel sits Wednesday, and Monday's edition sets the new week's line.
🧬 Rare Disease
The FDA approved the first Sanfilippo treatment two days ahead of its own deadline. RARE
Fayuvi (rebisufligene etisparvovec-hopf), the single dose AAV9 gene therapy formerly known as UX111, is approved for the neurologic manifestations of MPS IIIA in pediatric patients with preserved neurodevelopmental function. In Transpher A, treated patients scored 23.5 points above natural history on the Bayley-III cognitive scale, p<0.0001, from a 17 patient modified intention to treat group against 27 natural history controls. A rare pediatric Priority Review Voucher came with the approval, shipping to Qualified Treatment Centers starts within 30 to 60 days, and the price was not disclosed. The 2025 rejection was about manufacturing, and the approved product is made at the same Bedford and Columbus sites, now cured, which is the quiet achievement here. RARE closed at 14.50, up 12.6 percent, before the evening release crossed; Friday is the first session in which the approval itself trades.
🫀 Cardiorenal
Bayer turned a 242 patient surrogate trial into a 30 year first for type 1 diabetes kidney disease.
Kerendia (finerenone) is now approved to reduce urinary albumin to creatinine ratio in adults with CKD associated with type 1 diabetes, which Bayer calls the first new FDA approved treatment for that population in more than 30 years. FINE-ONE, in 242 adults, cut UACR 22 percent at three months and 28 percent at six months, p=0.0001, with hyperkalemia at 10.1 versus 3.3 percent. It is the fourth Kerendia indication, and Fierce reports Q2 sales grew 83 percent year over year against a roughly $3 billion peak projection. The regulatory read: a surrogate endpoint carried a full label into a population that outcomes trials skipped for three decades, the same UACR logic the agency has been extending across kidney disease all year.
🤫 Capital Markets
Amylyx's greenshoe window expired the only way it still could: silently. AMLX
No closing or exercise disclosure had surfaced as of Thursday night, with the company's SEC filings, newsroom, and the wires checked. The August 8-K set the terms: 14,090,000 shares at $35.50, an option for up to 2,113,500 more inside 30 days, and net proceeds of about $471.7 million, or $542.5 million with a full exercise. AMLX has now closed below the offer price in all fourteen sessions since pricing, Thursday at 33.94, up 4.0 percent on no news we could find. An option nobody can profitably exercise needs no announcement, and the roughly $70.8 million gap between those two proceeds figures is what the silence cost. The avexitide NDA remains guided for year end; the offering's final share count now surfaces in the Q3 filings rather than a press release.
💰 Deals
Pharma spent Thursday buying discovery engines, not drugs. NVO | RHHBY
Novo signed a multi target oral macrocycle pact with Copenhagen's Orbis Medicines worth up to $1.4 billion in upfront and milestone payments plus tiered royalties and an equity stake, with the release stating only the ceiling and no upfront broken out. Roche paid Dualitas Therapeutics $36.5 million upfront, in a deal worth up to about $1 billion with milestones per Fierce, to functionally screen more than 300,000 bispecific target pairs in immunology and inflammation. And SK Biopharmaceuticals licensed 1ST-104, a preclinical oral LRRK2 and c-Abl inhibitor for Parkinson's disease, for $1.8 million upfront against a roughly $315 million back end, per Fierce. Add Monday's Sironax purchase and that is four platform deals in four sessions, every one structured so the milestones carry the biology risk.
🧪 Oncology
Roche won its Lunsumio confirmatory trial and kept every number.
Celestimo, the Phase 3 confirmatory trial of Lunsumio (mosunetuzumab) plus lenalidomide against rituximab plus lenalidomide in follicular lymphoma patients with at least one prior line, met its progression free survival primary endpoint with what Roche calls a statistically and clinically meaningful improvement. Overall survival is immature and no figures were disclosed, per Fierce on the basis of the company's release. The win supports converting Lunsumio's accelerated approval to full approval and moving the combination a line earlier. It also joins arlo-cel and DeLLphi-305 in the quarter's growing stack of positive pivotal results whose numbers are being held for a congress. December's hematology season is accumulating obligations.
📈 The Tape
Every silent recovery we flagged this week delivered, and the week's best data finished green. VERA | IONS | DFTX
VERA rose 7.9 percent to 34.27 on no new disclosure, back above the 34.05 close that preceded Tuesday's ORIGIN 3 print; the full round trip took three sessions. IONS gained 4.3 percent to 46.75, ending its three session slide without any news, which is what a positioning flow looks like when it finishes. DFTX closed at 38.68, 21 cents shy of completing its own round trip above 38.89. BBNX gave back 3.4 percent as the post clearance run ended. The whole sector traded green Thursday, with BHVN up 15.6 percent and GENB up 9.2 percent on no disclosures we could find. Exchange closes, our arithmetic, no causes assigned.
📋 Quick Hits
Electra Therapeutics raised $350 million in its IPO, per Endpoints, the 21st biotech IPO of 2026, funding a Phase 2/3 trial of ipsoprubart in secondary hemophagocytic lymphohistiocytosis; ETRA had not traded by Thursday's close and no pricing release had surfaced in our checks.
Lisata and Marea agreed to a stock for stock reverse merger with a $225 million private placement, per Fierce; Endpoints counts Marea plus North Immunology at $405 million in combined backing.
GSK licensed Chimagen's trispecific T cell engager for up to $750 million, per BioSpace, announced September 15, and is cutting about 650 jobs as its Dresden vaccine manufacturing site closes.
Medtronic launched the exchange offer completing the MiniMed separation on September 14, swapping up to 80.1 percent of its remaining stake at a 7 percent discount through October 9, per MedTech Dive.
Grail's advisory committee briefing documents were still not posted as of Thursday night, with the panel Wednesday; GRAL closed up 6.4 percent with no disclosure found.
Still absent as of Thursday night: an Isembyld price document (SRRK logged a fourth straight decline), SERENA-4's medians, Etcamah and Bexlutry launch prices, a GSK flu Phase 3 start inside the company's own September window, and any Amgen readout date.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The complete Fayuvi label, Transpher A data, and safety table, and why the manufacturing sites are the real story of this approval
The early approval scoreboard: what two ahead of schedule FDA decisions in six days do to binary date positioning
The Amylyx offering math from the 8-K, including exactly what the silent expiry cost
The Forced Disclosure Week final scoreboard and Thursday's full tape table
📋 The Week in Review
Monday: AstraZeneca's Saturday SERENA-4 disclosure landed, eight days after Etcamah's approval, and WCLC opened with two B7-H3 datasets sharing an identical 0.46 hazard ratio.
Tuesday: Scholar Rock's Isembyld surfaced as a Friday evening approval, 19 days early, and WCLC's printers posted numbers while DeLLphi-305 stayed silent.
Wednesday: Amgen named no dates at Morgan Stanley and took our FAIL grade, the FDA approved Bexlutry as the first Lutathera equivalent, and Sanofi handed 20 medicines to Cheplapharm.
Thursday: Vera's ORIGIN 3 final analysis printed a 76 percent progression risk cut with every date attached, and Novartis ended lifonebart in ALS while buying Sironax's brain delivery platform for $125 million at closing.
Friday: Fayuvi approved two days early with a voucher, Kerendia's type 1 diabetes first, an up to $1.4 billion Novo macrocycle pact, and Amylyx's window expired silent.
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 Two early approvals in six days is not yet a pattern you can trade — but it forces one specific change in how you hold names into Q4 action dates, and we spell it out
💊 The final Forced Disclosure Week grade book: five forcing events, two documents, and the one behavioral tell that says which of December's withheld datasets to trust
📊 Four platform deals in four sessions share a common denominator that is not the science — and it points at what big pharma now thinks Phase 3 biology risk is worth
🎯 Plus the full catalyst calendar through 2027, rebuilt tonight: the UX111 row resolved early, the Amylyx row moved to the filings, and next week's dated events
Two approvals came early, three companies stayed silent, and the tape graded all five by Thursday's close. Next week the only party that publishes on schedule takes the pen back: briefing documents by Sunday, the first MCED panel Wednesday. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →